(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 163.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 26.22%.
Cytokinetics's revenue in 2025 is $19,218,000.On average, 22 Wall Street analysts forecast CYTK's revenue for 2025 to be $10,228,589,364, with the lowest CYTK revenue forecast at $7,958,634,806, and the highest CYTK revenue forecast at $19,289,896,365.  On average, 20 Wall Street analysts forecast CYTK's revenue for 2026 to be $16,808,197,217, with the lowest CYTK revenue forecast at $5,851,937,357, and the highest CYTK revenue forecast at $29,345,674,436.  
In 2027, CYTK is forecast to generate $46,206,419,662 in revenue, with the lowest revenue forecast at $32,620,370,810 and the highest revenue forecast at $84,644,093,914.